TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00727740
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
Study: NCT00727740
Drug: Placebo suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
Study: NCT04153929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for Injection
Study: NCT00753623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
Study: NCT02292472
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inject intramuscularly once in visit 2
Study: NCT00607581
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide: 500 mg orally on days 1, 8, 15
Study: NCT01465763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plabebo oral BID
Study: NCT00770900
Drug: Comparator: placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
Study: NCT04532567
Drug: GLPG1205
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1205 film-coated tablets
Study: NCT04532567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo film-coated tablets
Study: NCT01030432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, twice daily, 48 weeks
Study: NCT01030432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
Study: NCT01030432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, twice daily 24 weeks
Study: NCT00002489
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002489
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002489
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002489
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02903017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Via nasogastric tube, 100 mL
Study: NCT03197766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 15 μg/kg of placebo daily
Study: NCT03534895
Drug: Postoperative analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 1g + IV ketorolac 30mg
Study: NCT03534895
Drug: Rescue analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 2mg/Kg IV in 100mL of normal saline, if pain NRS\>3.
Study: NCT03534895
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration with 10mL of ropivacaine 0.75%, in open inguinal hernia repair
Study: NCT03534895
Drug: Analgesia at home
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen 1g 6/6h + ibuprofen 400mg 8/8h (+ rescue analgesia with tramadol 50mg 6/6h)
Study: NCT02987244
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide(750mg/m2) was administered intravenously on d1
Study: NCT02758743
Drug: Acetium Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release L-Cysteine to block smoke.derived acetaldehyde in saliva thereby inhibiting the formation of harmans
Study: NCT02758743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with no active substance will not have the effect on intervention device.
Study: NCT04678531
Drug: Baby shampoo
Normalized name: BABY SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baby shampoo will be used in 23 patients for 8 weeks and will be discontinued in the following 4 weeks.
Study: NCT00380315
Drug: AG1321001(drug)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02388347
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
Study: NCT03662269
Drug: indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: indomethacin (75mg, bid, po, 14days)
Study: NCT03662269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (75mg, bid, po, 14days)
Study: NCT01799720
Drug: Hypercholesterolemic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
Study: NCT00349466
Drug: CF101
Normalized name: CF101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally CF101 1mg
Study: NCT00349466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally matching Placebo
Study: NCT00487825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Study: NCT00487825
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
Study: NCT02358668
Drug: BTI320
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
Study: NCT02358668
Drug: BTI320 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03153150
Drug: Acenocoumarol
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
Study: NCT02904109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral administration of placebo mannitol for 8 days.
Study: NCT01443403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets administered orally once a day.
Study: NCT00390260
Drug: MK0966 / Duration of Treatment: 1 Days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00390260
Drug: Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00390260
Drug: Comparator: placebo (unspecified) / Duration of Treatment: 1 Days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03489005
Drug: BIA 5-1058
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets
Study: NCT01621243
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be dosed daily
Study: NCT03489005
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets administered as follows:~- placebo, as 12 × 0-mg tablets
Study: NCT01953445
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03510455
Drug: BGJ398
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGJ398, a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor will be orally administered over six 4-week cycles (4 weeks on drug continuously). After the initial dose, escalation/de- escalation of BGJ398 will be based on FGF- 23 blood levels and adjusted according to protocol procedures. The six cycles of BGJ398 will be followed by 3 months off the drug and an optional extension phase.
Study: NCT02018653
Drug: Calcium Alumina-Silicate (CASAD)
Normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram by mouth every 6 hours for up to 6 days.
Study: NCT02036138
Drug: Advanced Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00220064
Drug: Irinotecan, 5-Fluorouracil, Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03217734
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Tablet
Study: NCT03217734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT02447640
Drug: ADX48621
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
Study: NCT01063855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
Study: NCT03549611
Drug: Multimodal Oral Drug Regimen
Normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen of 4 pharmacologic agents that provides analgesia by acting on 4 different physiologic pain pathways
Study: NCT03549611
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 975mg
Study: NCT01037205
Drug: Respitose ML006 (DMV-Fonterra)
Normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL SPRAY [doTERRA sun]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose monohydrate
Study: NCT01342029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-1,000 mg po bid for 2 weeks
Study: NCT01458054
Drug: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2336805 and Omeprazole
Study: NCT01458054
Drug: Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2336805 and Ritonavir
Study: NCT00346996
Drug: insulin levemir / aspart
Approvals — FDA: no, EMA: no, PMDA: no
Description: for subcutaneous injection
Study: NCT00346996
Drug: human insulin /insulin isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: for subcutaneous injection
Study: NCT03106454
Drug: Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Oral Contraceptive Pill. Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg
Study: NCT02767752
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02595320
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).~Capecitabine will be given to participants in group B at 1250 mg/m2 OR 1000 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7).
Study: NCT00854204
Drug: TMC114; TMC41629
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00345098
Drug: SR58611A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02973360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT00895843
Drug: Brufen retard
Normalized name: Brufen Retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 2 x 800mg tablets 2 hours prior to surgery
Study: NCT00895843
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
Study: NCT04446091
Drug: Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs for colorectal mucinous adenocarcinoma
Study: NCT02469155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01424813
Drug: Placebo MDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Study: NCT02373579
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
Study: NCT01722318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04149431
Drug: Derinat
Normalized name: Serine
DrugBank: Serine (DB00133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: desoxyribonucleate sodium
Study: NCT01357642
Drug: Epinephrine inhalation aerosol
Normalized name: epinephrine Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine inhalation aerosol, 125 mcg/inhalation, 2 inhalations QID at 4 - 6 hour intervals
Study: NCT01357642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for epinephrine inhalation aerosol, formulation without epinephrine
Study: NCT01572740
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
Study: NCT00478192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: premix bag
Study: NCT02824354
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
Study: NCT01689571
Drug: CHF6001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01689571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03537547
Drug: FDA-approved antidepressant or antipsychotic treatment
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant is treated with medications included in the GeneSight Psychotropic product.
Study: NCT00077389
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00858689
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
Study: NCT01038427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray administered once daily (4 actuations) for 14 days.
Study: NCT02202785
Drug: MLN0264
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN0264 IV infusion
Study: NCT03399253
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
Study: NCT01549834
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose
Study: NCT01549834
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose
Study: NCT01549834
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04539483
Drug: HDIT101 (blinded therapy)
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with with topical HDIT101 (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
Study: NCT04539483
Drug: Placebo (blinded therapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with with topical placebo (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
Study: NCT02686619
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
Study: NCT01378520
Drug: inert powder
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral once
Study: NCT02337205
Drug: KX2-391 Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
Study: NCT04288349
Drug: epinephrine + ropivacaine +saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine + ropivacaine +saline
Study: NCT04288349
Drug: epinephrine + saline
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epinephrine + saline
Study: NCT04228926
Drug: ZKY001 eye drops 0.3g:0.006mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZKY001 eye drops of 0.002% continuously for up to 14±2 days after Corneal endothelial transplantation
Study: NCT04228926
Drug: ZKY001 eye drops 0.3g:0.012mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZKY001 eye drops of 0.004% continuously for up to 14±2 days after Corneal endothelial transplantation
Study: NCT00373451
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.v. bolus of 70 units/kg/body weight of unfractionated heparin
Study: NCT02336425
Drug: QGE031
Approvals — FDA: no, EMA: no, PMDA: no
Description: QGE031 120 mg per 1 mL liquid in vial
Study: NCT02336425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to QGE031 0 mg per 1 mL liquid in vial
Study: NCT03749135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00439192
Drug: ELB245
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00996606
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants may continue on a stable dose of their current DMARD therapy as prescribed. The choice of DMARD is at the discretion of the treating physician and is not specified by the protocol.
Study: NCT01067846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
Study: NCT00753064
Drug: Antiscorpion venom serum(AScVS).
Approvals — FDA: no, EMA: no, PMDA: no
Description: AScVS therapy group~If the score is 5 and if the patient belongs to pediatric group(\>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml distilled water and given over a period of 4 to 5 minutes.~According to the scores 1 vial for pediatric and 2 vials for adult patient will be increased as shown below:~Vials of AScVS Composite score Child Adult 5-10 2 4 \> 10-15 3 6 \>15- 21 4 8
Study: NCT02910518
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02910518
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: intravenous
Study: NCT02810119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00577057
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01878396
Drug: Anti-B-RAF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00794625
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
Study: NCT03623022
Drug: Clinical Center Reference Endotoxin (CCRE)
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.
Study: NCT03623022
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
Study: NCT00259376
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT04048070
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One kind of opioid drugs, 1.5μg/kg, and recorded the drug consumption after surgery